AZN - Acer Therapeutics: Deriving Value By Developing Therapies For Rare Diseases
- Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious, rare, and life-threatening diseases.
- Acer submitted an NDA for its lead drug candidate ACER-001 for treatment of UCDs in early August.
- Acer expects notification regarding potential acceptance for filing from the FDA approximately 60 days after NDA submission and subsequent substantive review. If approved, Acer could launch ACER-001 in mid-2022.
- Other than UCDs, Acer is developing therapies for MSUD, iVMS, vEDS, and infectious diseases. All these diseases have a market that is niche and untapped, characterized by low competition.
- Assuming a base case revenue of $40 million in 2022 and a P/S ratio of 5.0x, the company’s intrinsic value would be ~$122 million or $8.70 per share, indicating an upside close to 3.5x.
For further details see:
Acer Therapeutics: Deriving Value By Developing Therapies For Rare Diseases